Company: INTS
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001567264-25-000103
Chunk: 37

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 37
---
 revise the dosing regimen for patients receiving INT230-6.(d)Consulting & Other includes research and development consulting costs and travel-related costs. (e)Other includes facility expenses, office supplies, computer and software related costs, public relations costs, and travel-related costs. 

(f)Other segment items include interest income, interest expense, and foreign exchange gains and losses. 

13

Note 13.    Subsequent Events

ATM Sales Agreement IssuancesSubsequent to September 30, 2025, the Company issued 5,930,344 shares of common stock under the ATM Sales Agreement for net proceeds of $2.0 million. October 2025 Registered Direct OfferingOn October 30, 2025, the Company entered into a Securities Purchase Agreement with an institutional investor, pursuant to which the Company agreed to issue and sell, in a registered direct offering by the Company directly to the investor 5,000,000 shares of common stock at a price of $0.80 per share, for aggregate gross proceeds of $4.0 million before deducting the placement agent’s fees and related offering expenses.

14

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of our financial condition and results of operations should be read together with our financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q and in our 2024 Annual Report. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report on Form 10-Q, including information with respect to our plans and strategy for our business and financing needs, includes forward-looking statements that involve risks and uncertainties. Such statements should be read together with the “Risk Factors” sections of this Quarterly Report on Form 10-Q and the 2024 Annual Report, which discuss important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. See “Cautionary Statement Regarding Forward-Looking Statements”. 

Overview

We are a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction leading to anti-cancer immune activation. Our new approach involves the direct injection into tumors of a unique product created from our DfuseRxSM discovery platform.

Intratumoral (“IT”) treatment, or treatment designed to contain a drug inside a tumor without spreading to the rest of the body, has been an objective of clinicians since discovery of